Cited by 96

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The cellular function of SCAP in metabolic signaling

Lee, Sun Hee, Lee, Jae-Ho, Im, Seung-Soon·2020·Experimental & Molecular Medicine

Abstract

Sterol regulatory element binding protein (SREBP) cleavage activating protein (SCAP) is a key regulator of SREBP maturation. SCAP induces translocation of SREBP from the endoplasmic reticulum to the Golgi apparatus, allowing it to regulate cellular triglyceride and cholesterol levels. Previous studies have shown that suppression of SREBP activation in SCAP conditional knockout mice reduced the accumulation of intracellular triglycerides, which eventually causes the development of metabolic diseases such as atherosclerosis, diabetes, hepatic steatosis, and insulin resistance. However, despite the significance of SCAP as a regulator of SREBP, its function has not been thoroughly discussed. In this review, we have summarized the function of SCAP and its regulatory proteins. Furthermore, we discuss recent studies regarding SCAP as a possible therapeutic target for hypertriglyceridemia and hyperlipidemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-020-0430-0

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic model of the domain organization and processing mechanism of SCAP. a SCAP proteins consist of an amino-terminal domain of eight transmembrane helices and a carboxyl-terminal WD40 domain. Transmembrane helices 2-6 of SCAP constitute a sterol-sensing domain. b When mammalian cells are deprived of cholesterol, SCAP escorts SREBPs in COPII vesicles from the ER to the Golgi. Two Golgi proteases (S1P and S2P) then sequentially cleave SREBPs. The NH2-terminal region of SREBPs moves to the nucleus and activates the transcription of target genes. To date, SREBPs are known to directly enhance the transcription of more than 30 genes needed for the uptake and synthesis of cholesterol, fatty acids, triglycerides, and phospholipids. Despite acting in diverse biosynthetic pathways, the activity of each SREBP isoform is regulated by sterols and SCAP. COPII, coat protein II; ER, endoplasmic reticulum; INSIG, insulin-induced gene; S1P, site-1 protease; S2P, site-2 protease; SCAP, SREBP cleavage-activating protein; SRE, sterol regulatory element; SREBP, Sterol regulatory element-binding protein.
Fig. 1 Schematic model of the domain organization and processing mechanism of SCAP. a SCAP proteins consist of an amino-terminal domain of eight transmembrane helices and a carboxyl-terminal WD40 domain. Transmembrane helices 2-6 of SCAP constitute a sterol-sensing domain. b When mammalian cells are deprived of cholesterol, SCAP escorts SREBPs in COPII vesicles from the ER to the Golgi. Two Golgi proteases (S1P and S2P) then sequentially cleave SREBPs. The NH2-terminal region of SREBPs moves to the nucleus and activates the transcription of target genes. To date, SREBPs are known to directly enhance the transcription of more than 30 genes needed for the uptake and synthesis of cholesterol, fatty acids, triglycerides, and phospholipids. Despite acting in diverse biosynthetic pathways, the activity of each SREBP isoform is regulated by sterols and SCAP. COPII, coat protein II; ER, endoplasmic reticulum; INSIG, insulin-induced gene; S1P, site-1 protease; S2P, site-2 protease; SCAP, SREBP cleavage-activating protein; SRE, sterol regulatory element; SREBP, Sterol regulatory element-binding protein.CC BY · PubMed Central
Fig. 2 The function of SREBP-SCAP in lipid metabolism. Activation of SCAP–SREBP as the master regulator of lipid metabolism stimulates the transcription of enzymes required for de novo lipogenesis and receptors that mediate the uptake of fatty acids released by lipolysis.
Fig. 2 The function of SREBP-SCAP in lipid metabolism. Activation of SCAP–SREBP as the master regulator of lipid metabolism stimulates the transcription of enzymes required for de novo lipogenesis and receptors that mediate the uptake of fatty acids released by lipolysis.CC BY · PubMed Central
Fig. 3 Small-molecule inhibitors of the SCAP-SREBP complex. a Fatostatin is a chemical inhibitor of the SREBP pathway that directly binds SCAP and blocks its ER-to-Golgi transport. b Betulin enhances the binding of SCAP with INSIGs, thereby promoting the retention of SREBPs in the ER. c Xanthohumol, a prenylated flavonoid in hops, is an antagonist of SREBP.
Fig. 3 Small-molecule inhibitors of the SCAP-SREBP complex. a Fatostatin is a chemical inhibitor of the SREBP pathway that directly binds SCAP and blocks its ER-to-Golgi transport. b Betulin enhances the binding of SCAP with INSIGs, thereby promoting the retention of SREBPs in the ER. c Xanthohumol, a prenylated flavonoid in hops, is an antagonist of SREBP.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 49

  1. Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology. Nat. Rev. Endocrinol. 13, 710–730 (2017). · DOI · Paper page
  2. Goldstein, J. L., DeBose-Boyd, R. A. & Brown, M. S. Protein sensors for membrane sterols. Cell 124, 35–46 (2006). · DOI · Paper page
  3. Goldstein, J. L., Rawson, R. B. & Brown, M. S. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch. Biochem. Biophys. 397, 139–148 (2002). · DOI · Paper page
  4. Motamed, M. et al. Identification of luminal Loop 1 of Scap protein as the sterol sensor that maintains cholesterol homeostasis. J. Biol. Chem. 286, 18002–18012 (2011). · DOI
  5. Radhakrishnan, A., Sun, L. P., Kwon, H. J., Brown, M. S. & Goldstein, J. L. Direct binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domain. Mol. Cell. 15, 259–268 (2004). · DOI · Paper page
  6. Sakai, J., Nohturfft, A., Goldstein, J. L. & Brown, M. S. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. J. Biol. Chem. 273, 5785–5793 (1998). · DOI
  7. Yang, T. et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110, 489–500 (2002). · DOI · Paper page
  8. Brown, M. S., Radhakrishnan, A. & Goldstein, J. L. Retrospective on cholesterol homeostasis: the central role of scap. Annu. Rev. Biochem. 87, 783–807 (2018). · DOI · Paper page
  9. Zhang, Y., Motamed, M., Seemann, J., Brown, M. S. & Goldstein, J. L. Point mutation in luminal loop 7 of Scap protein blocks interaction with loop 1 and abolishes movement to Golgi. J. Biol. Chem. 288, 14059–14067 (2013). · DOI
  10. Espenshade, P. J. & Hughes, A. L. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401–427 (2007). · DOI · Paper page
  11. Sokolov, A. & Radhakrishnan, A. Accessibility of cholesterol in endoplasmic reticulum membranes and activation of SREBP-2 switch abruptly at a common cholesterol threshold. J. Biol. Chem. 285, 29480–29490 (2010). · DOI · Paper page
  12. Afonso, M. S. et al. Molecular pathways underlying cholesterol homeostasis. Nutrients 10, 760 (2018). · DOI · Paper page
  13. Dong, X. Y., Tang, S. Q. & Chen, J. D. Dual functions of Insig proteins in cholesterol homeostasis. Lipids Health Dis. 11, 173 (2012). · DOI
  14. Bi, X., Corpina, R. A. & Goldberg, J. Structure of the Sec23/24-Sar1 pre-budding complex of the COPII vesicle coat. Nature 419, 271–277 (2002). · DOI
  15. Sun, L. P., Li, L., Goldstein, J. L. & Brown, M. S. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J. Biol. Chem. 280, 26483–26490 (2005). · DOI · Paper page
  16. Radhakrishnan, A., Ikeda, Y., Kwon, H. J., Brown, M. S. & Goldstein, J. L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl Acad. Sci. USA 104, 6511–6518 (2007). · DOI · Paper page
  17. Nohturfft, A., Yabe, D., Goldstein, J. L., Brown, M. S. & Espenshade, P. J. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell 102, 315–323 (2000). · DOI
  18. Espenshade, P. J., Li, W. P. & Yabe, D. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. Proc. Natl Acad. Sci. USA 99, 11694–11699 (2002). · DOI · Paper page
  19. Ye, J. & DeBose-Boyd, R. A. Regulation of cholesterol and fatty acid synthesis. Cold Spring Harb. Perspect. Biol 3, a004754 (2011). · DOI · Paper page
  20. van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9, 112–124 (2008). · DOI · Paper page
  21. Breslow, D. K. & Weissman, J. S. Membranes in balance: mechanisms of sphingolipid homeostasis. Mol. Cell. 40, 267–279 (2010). · DOI
  22. Gong, Y. et al. Sterol-regulated ubiquitination and degradation of Insig-1 creates a convergent mechanism for feedback control of cholesterol synthesis and uptake. Cell Metab. 3, 15–24 (2006). · DOI · Paper page
  23. McFarlane, M. R., Liang, G. & Engelking, L. J. Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine. J. Biol. Chem. 289, 2148–2156 (2014). · DOI
  24. DeBose-Boyd, R. A. & Ye, J. SREBPs in lipid metabolism, insulin signaling, and beyond. Trends Biochem. Sci. 43, 358–368 (2018). · DOI
  25. Moon, Y. A. et al. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15, 240–246 (2012). · DOI · Paper page
  26. Zhang, X., Ji, X., Wang, Q. & Li, J. Z. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Protein Cell 9, 164–177 (2018). · DOI
  27. Mu, W. et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front. Pharm. 9, 1566 (2018). · DOI
  28. Ito, A. et al. Cholesterol accumulation in CD11c(+) Immune cells is a causal and targetable factor in autoimmune disease. Immunity 45, 1311–1326 (2016). · DOI
  29. Westerterp, M. et al. Cholesterol accumulation in dendritic cells links the inflammasome to acquired immunity. Cell Metab. 25, 1294–1304 e1296 (2017). · DOI · Paper page
  30. Guo, C. et al. Cholesterol homeostatic regulator SCAP-SREBP2 Integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages. Immunity 49, 842–856 e847 (2018). · DOI · Paper page
  31. Ouyang, N. et al. Dysfunction of cholesterol sensor SCAP promotes inflammation activation in THP-1 macrophages. Exp. Cell Res. 367, 162–169 (2018). · DOI · Paper page
  32. Uttarwar, L., Gao, B., Ingram, A. J. & Krepinsky, J. C. SREBP-1 activation by glucose mediates TGF-beta upregulation in mesangial cells. Am. J. Physiol. Ren. Physiol. 302, F329–F341 (2012). · DOI
  33. Yuan, Y. et al. Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro. Am. J. Physiol. Ren. Physiol. 301, F236–F243 (2011). · DOI
  34. Zhou, C. et al. Enhanced SCAP glycosylation by inflammation induces macrophage foam cell formation. PLoS ONE 8, e75650 (2013). · DOI
  35. York, A. G. et al. Limiting cholesterol biosynthetic flux spontaneously engages Type I IFN signaling. Cell 163, 1716–1729 (2015). · DOI · Paper page
  36. Boshuizen, M. C. et al. Interferon-beta promotes macrophage foam cell formation by altering both cholesterol influx and efflux mechanisms. Cytokine 77, 220–226 (2016). · DOI
  37. Chen, W. et al. ER adaptor SCAP translocates and recruits IRF3 to perinuclear microsome induced by cytosolic microbial DNAs. PLoS Pathog. 12, e1005462 (2016). · DOI
  38. Engelking, L. J., Cantoria, M. J., Xu, Y. & Liang, G. Developmental and extrahepatic physiological functions of SREBP pathway genes in mice. Semin. Cell Dev. Biol. 81, 98–109 (2018). · DOI
  39. McFarlane, M. R. et al. Scap is required for sterol synthesis and crypt growth in intestinal mucosa. J. Lipid Res. 56, 1560–1571 (2015). · DOI · Paper page
  40. Tang, J. J. et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 13, 44–56 (2011). · DOI · Paper page
  41. Casaschi, A. et al. The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J. Nutr. 134, 1340–1346 (2004). · DOI
  42. Miyata, S., Inoue, J., Shimizu, M. & Sato, R. Xanthohumol improves diet-induced obesity and fatty liver by suppressing sterol regulatory element-binding protein (SREBP) Activation. J. Biol. Chem. 290, 20565–20579 (2015). · DOI
  43. Mustafa, M., Wang, T. N., Chen, X., Gao, B. & Krepinsky, J. C. SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction. Am. J. Physiol. Ren. Physiol. 311, F614–F625 (2016). · DOI
  44. Kamisuki, S. et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 16, 882–892 (2009). · DOI · Paper page
  45. Cheng, X., Li, J. & Guo, D. SCAP/SREBPs are central players in lipid metabolism and novel metabolic targets in cancer therapy. Curr. Top. Med. Chem. 18, 484–493 (2018). · DOI
  46. Pharr, P. N. & Ogawa, M. Enhancement of the proliferation of murine fetal liver erythroid progenitors by infection with Harvey sarcoma virus. Leukemia 4, 210–215 (1990).
  47. Choi, Y., Kawazoe, Y., Murakami, K., Misawa, H. & Uesugi, M. Identification of bioactive molecules by adipogenesis profiling of organic compounds. J. Biol. Chem. 278, 7320–7324 (2003). · DOI
  48. Liu, M. et al. Xanthohumol, a prenylated chalcone from beer hops, acts as an alpha-glucosidase inhibitor in vitro. J. Agric. Food Chem. 62, 5548–5554 (2014). · DOI
  49. Mahli, A. et al. Therapeutic application of micellar solubilized xanthohumol in a western-type diet-induced mouse model of obesity, diabetes and non-alcoholic Fatty liver disease. Cells 8, 359 (2019). · DOI

Cited by

Sorted by citations

See all 96

Metadata

Authors
Lee, S. H., Lee, J.-H., & Im, S.-S.
Venue
Experimental & Molecular Medicine
Published
2020-05
Volume
52
Issue
5
Pages
724-729
ISSN
  • 1226-3613
  • 2092-6413
Cited by
96
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review